8-K: Genprex Announces 1:22 Reverse Stock Split and Clinical Updates

Genprex, Inc. files an 8-K detailing a 1-for-22 reverse stock split effective July 16, 2026, and provides updates on its Acclaim-1 and Acclaim-3 clinical trials.

Summary

• Genprex, Inc. has filed a Form 8-K to announce a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026.
• The reverse stock split aims to address the company's compliance with Nasdaq's minimum bid price requirement.
• The company estimates approximately 504,936 shares of common stock will be outstanding immediately after the split.
• Updates on clinical trials include ongoing enrollment in the Phase 2a expansion of the Acclaim-1 trial for NSCLC and the Phase 2 expansion of the Acclaim-3 trial for ES-SCLC.
• The Acclaim-1 trial is investigating REQORSA in combination with AstraZeneca's Tagrisso, with promising progression-free survival noted in some Phase 1 patients.
• Research has identified TROP-2 and PTEN as potential biomarkers for predicting patient response to REQORSA.
• The Acclaim-3 trial is evaluating REQORSA with Genentech's Tecentriq, with an interim analysis expected in the first half of 2027.
• The company received a delisting notice from Nasdaq due to failure to meet the minimum bid price requirement and has requested a hearing.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant risk of Nasdaq delisting, despite some positive clinical trial developments and the implementation of a reverse stock split.

Positives

• Three patients in the Phase 1 dose escalation of Acclaim-1 showed prolonged progression-free survival, with one achieving a partial response and remaining on treatment for approximately 46 months.
• Preclinical and clinical data suggest TROP-2 and PTEN may serve as predictive biomarkers for REQORSA response, potentially guiding patient selection.
• FDA Fast Track Designation has been granted for both the Acclaim-1 and Acclaim-3 treatment combinations.
• FDA Orphan Drug Designation has been received for the Acclaim-3 trial.

Negatives

• The company received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.
• There is no assurance that the reverse stock split will result in regaining compliance with Nasdaq's listing requirements or that the bid price will be maintained.
• A delisting from Nasdaq could materially reduce the stock price, negatively impact the ability to raise capital, and reduce investor confidence.

Risks

• Failure to regain compliance with Nasdaq's continued listing requirements could lead to delisting, negatively impacting the stock price and ability to access capital markets.
• The announcement and implementation of the reverse stock split could negatively affect the stock price.
• There is no guarantee that the reverse stock split will result in regaining compliance with the minimum bid price requirement.
• Liquidity may be adversely affected by the reduced number of outstanding shares post-reverse stock split.
• The company's ability to advance clinical development, manufacturing, and commercialization of product candidates is subject to known and unknown risks and uncertainties.

Future Outlook

The company is focused on advancing its oncology and diabetes gene therapy programs, including enrolling and treating patients in its Acclaim-1 and Acclaim-3 clinical trials. The company plans to further evaluate TROP-2 expression as a potential biomarker for REQORSA and anticipates an interim analysis for the Acclaim-3 trial in the first half of 2027. Genprex is also actively working to regain compliance with Nasdaq's minimum bid price requirement through the implemented reverse stock split and other potential steps.

Management Comments

• The company intends to continue to monitor the closing bid price of its Common Stock and take definitive steps in an effort to evidence and regain compliance with the Bid Price Requirement, including by implementing effective July 16, 2026 the one-for-twenty-two (1:22) Reverse Stock Split of our Common Stock.
• There can be no assurance that the Panel will grant our request for continued listing or that we will be able to evidence compliance with the Bid Price Requirement within any extension period that may be granted by the Panel, or that we will be able to maintain compliance with the Bid Price Requirement or the other Nasdaq continued listing requirements.

Industry Context

StockSavvy.ai notes that reverse stock splits are often implemented by companies facing delisting threats, particularly in the biotechnology sector where clinical trial progress and regulatory approvals are key drivers of valuation. The identification of predictive biomarkers like TROP-2 and PTEN is a critical trend in precision medicine, aiming to improve drug efficacy and patient outcomes.

Corporate Governance

Legal Proceedings

• Genprex has requested a hearing before a Nasdaq Hearings Panel to appeal the determination to delist its securities.

Stakeholder Impact

• Shareholders: The reverse stock split will reduce the number of outstanding shares and increase the per-share price, potentially impacting market perception and liquidity. Delisting from Nasdaq would significantly reduce share value and access to capital.
• Employees: Potential delisting could impact morale and the value of stock options.
• Creditors/Suppliers: A delisting and subsequent decline in stock price could reduce investor confidence, potentially affecting the company's ability to secure future financing or favorable terms.

Next Steps

• Continue enrolling and treating patients in the Phase 2a expansion of the Acclaim-1 clinical trial.
• Continue enrolling and treating patients in the Phase 2 expansion of the Acclaim-3 clinical trial.
• Complete enrollment of the first 25 patients for interim analysis in the Acclaim-3 Phase 2 expansion by the end of 2026.
• Perform interim analysis for the Acclaim-3 Phase 2 expansion in the first half of 2027.
• Further evaluate high (3+) TROP-2 expression as a potential biomarker for REQORSA.
• Take definitive steps to evidence and regain compliance with Nasdaq's Bid Price Requirement.
• Attend Nasdaq Hearings Panel hearing regarding delisting notice.

Key Dates

Recommendation

The company is facing a significant risk of delisting from Nasdaq, which could severely impact its stock price and ability to raise capital. While there are promising clinical developments and biomarker research, these are early-stage and do not outweigh the immediate delisting threat. A 'hold' recommendation reflects the uncertainty and high risk associated with the company's current situation, pending clearer progress on Nasdaq compliance and clinical trial outcomes.

Keywords

Genprex, 8-K, Reverse Stock Split, Nasdaq, Delisting, REQORSA, NSCLC, Gene Therapy